media – Page 64 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Nature Journal | Revealing the Cell Membrane Protein Interactions of Endogenous GLP-1 Receptors!

As a drug therapy target for obesity and type 2 diabetes, glucagon like peptide-1 receptor (GLP-1R) is widely distributed in many tissues and has cell type specific physiological functions. For example, GLP-1R mainly regulates insulin secretion and cell proliferation in pancreatic islets, and has functions such as appetite suppression, neuroprotection, and anti-inflammatory in the brain. Considering that the maturation, localization, activation, and endocytosis of receptors are all influenced by protein interactions, exploring the interactions between receptors and other membrane proteins on the cell surface can provide important clues for the study of the regulatory mechanism of GLP-1R. However, due to the low expression levels and transient and weak interactions of most membrane receptors, the study of the interaction between endogenous GLP-1R and cell membrane proteins requires the development of new research methods. On September 3, 2024, the iHuman Institute of ShanghaiTech University and the research group led by Shui Wenqing ...
- Source: drugdu
- 68
- September 12, 2024
Great earthquake! AlphaProteo breaks doubts! Will become a cancer killer! Leading the way in brand new protein design!

Heavy weight! DeepMind is scaling up again! AlphaFold dominates the field of protein prediction, and AlphaFold 3 breaks through its limitations by predicting all living molecules. When it was released, there were voices claiming that AlphaFold 3’s structured prediction and generation would accelerate the development of AI driven drug design. Now, DeepMind has scaled up its strategy by releasing AlphaProteo for the design of new proteins. AlphaProteo is the first AI system designed specifically for designing novel high-intensity protein conjugates, capable of generating conjugates of multiple target proteins. This system significantly improves the success rate, even 3 to 300 times stronger than existing methods. Especially for the VEGF-A protein related to cancer and diabetes complications, AlphaProteo is the first AI tool to design successful conjugates. In addition, it can effectively bind to various proteins related to infection, cancer, inflammation, and autoimmune diseases, such as BHRF1, SARS-CoV-2 spike protein, IL-7R α, ...
- Source: drugdu
- 95
- September 12, 2024
Orthopedic giant, head coach of Greater China region resigns

Recently, global orthopedic giant Xerox announced that Mr. Hu Hai, Managing Director of Xerox Greater China, has decided to leave Xerox on September 26th to seek external development opportunities. At present, Hu Hai has not announced where his next destination will be, and Shi Lehui has not yet announced a new successor. Retired veteran resigns In September 2021, Xerox announced the departure of its Managing Director for Greater China, Alaeddin Ahram, and the new Managing Director for Greater China, Hu Hai, took office on September 27th. Hu Hai is a veteran in the field of medical devices, with over 30 years of experience in the field, especially in orthopedics. Prior to joining Xerox, he had extensive work experience in several giant companies, including serving as Vice President of the Joint Division in China at Johnson&Johnson Medical, Vice President of Depuy Synthes in China at Johnson&Johnson Orthopedics, the first CEO and ...
- Source: drugdu
- 66
- September 12, 2024
Optical equipment giant, entering the ‘ophthalmic metaverse’

Recently, optical giant Zeiss announced that it has reached a cooperation agreement with Swiss AR/VR company Creal to jointly develop a new digital vision healthcare platform based on light field display technology, planning to completely revolutionize existing vision diagnosis and treatment procedures. Light field display is a method that utilizes ray tracing to reconstruct 3D scenes in space, and is currently the most likely practical 3D display technology. Compared with holographic display technology, which is also a true 3D display technology, light field display has smaller data volume, lower cost, and smaller volume. Zeiss will introduce CREAL’s light field display technology to create a device that can digitally reproduce real refractive testing. The new device will be able to virtually simulate traditional glasses and contact lenses, eliminating the need to switch lenses repeatedly. Objects in front of us will be displayed at different focal lengths, and through precise digital imaging, ...
- Source: drugdu
- 64
- September 12, 2024
BioPlus-Interphex Korea

Organiser：Reed Exhibitions Time：October 15 – 17, 2025 Address：513, Yeongdong-daero, Gangnam-gu, Seoul Exhibition hall：COEX Product range: Pharmaceutical Raw Materials & Ingredients: Pharmaceutical raw materials, Active Pharmaceutical Ingredients (APIs), intermediates, additives, functional ingredients, natural extracts, fine chemicals, contract manufacturing/outsourcing/OEM, formulations, various analytical services and equipment, as well as other raw materials, related services, and technologies. Biopharmaceuticals: Laboratory equipment/reagents, biological agents, drug discovery and development, biotechnology, genomics, and more. About BioPlus-Interphex Korea： BioPlus-Interphex Korea is a biopharmaceutical exhibition showcasing the “value chain of biopharmaceuticals” and promoting overseas expansion through the establishment of a global business network. It is a collaborative event between BIOPLUS, led by KoreaBIO, the leading organization in Korea’s bioindustry, and INTERPHEX, the international pharmaceutical exhibition brand.
- Source: drugdu
- 239
- September 12, 2024
Lianying ranks first in domestic production

Recently, the US FDA updated the list of authorized artificial intelligence and machine learning (AI/ML) medical devices. This list is a barometer of the health status of the artificial intelligence industry, and updates show that the FDA is maintaining a rapid pace of authorization. In the past few years, the FDA’s AI authorization has maintained double-digit growth, which reflects the increasing number of submissions received by the FDA from AI developers. AI/ML medical equipment explosion In the past, the FDA usually updated the list of approved AI/ML devices once a year, but with the frequent changes and approvals of artificial intelligence technology, the FDA has increased the frequency of updating the list. This list update includes 61 new approvals, including products approved between March 31st and June 25th. Similar to previous updates, applications targeting radiology accounted for the majority of the new licenses, with 44 products on the list since ...
- Source: drugdu
- 98
- September 11, 2024
Donated 160 million yuan to the Qinghai-Tibet Plateau

Under the guidance of the Central United Front Work Department, the Beijing Tongxin Gongzhu Public Welfare Foundation’s “Together, Forge a Chinese Heart” fund launched the 2024 “Together, Forge, Warm the Plateau” series of donation activities on the 5th, sending medical supplies worth 163 million yuan to the people in the Qinghai-Tibet Plateau. In early July, the Beijing Tongxin Gongzhu Public Welfare Foundation invited more than 800 medical experts from the capital, including Dong Jiahong, an academician of the Chinese Academy of Engineering, and Wang Jianliu, secretary of the Party Committee of Peking University People’s Hospital, to Ganzi Tibetan Autonomous Prefecture, Sichuan Province to carry out the “Together, Forge a Chinese Heart” medical charity event. The event lasted for one week, and 90 free clinics were set up in 18 counties (cities) in Ganzi Prefecture, with 73,000 free clinics, 10.8 million yuan worth of medicines distributed, and 52 operations such ...
- Source: https://mp.weixin.qq.com/
- 111
- September 11, 2024
The world’s first! Kangfang Biological Double Anti First Line Treatment for NSCLC Defeats K-Drug

On September 8, 2024, Kangfang Biotechnology announced at the 2024 World Lung Cancer Congress the heavyweight research data of the registered Phase III clinical trial (HARMONI-2/AK112-303) of the company’s independently developed global first PD-1/VEGF bispecific antibody new drug, Ivoxidan, compared to pembrolizumab monotherapy for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with PD-L1 expression positive (PD-L1 TPS ≥ 1%). Ivoxidan became the world’s first drug to demonstrate significantly better efficacy than pembrolizumab in a single drug head to head Phase III clinical trial. Affected by this news, the stock price of Kangfang Biotechnology has risen by 14%. AK112-303/HARMONI-2 (CTR20222137) is a registered phase III randomized, double-blind clinical trial conducted in China to evaluate the first-line treatment of locally advanced or metastatic NSCLC with PD-L1 expression positive (PD-L1TPS ≥ 1%) compared to Ibuprofen (PD-1/VEGF) monotherapy. The primary endpoint was PFS assessed by IRRC according to ...
- Source: drugdu
- 99
- September 11, 2024
635 million US dollars! Anmai Biological BCMA × CD3 Double Antibody Successfully Goes to Sea

Anmai Biotechnology announced that it has reached a licensing agreement with Vignette Bio for the T cell conjugation (TCE) molecule EMB-06 targeting BCMA. According to the agreement, Amway Bio will grant Vignette the exclusive right to develop and commercialize EMB-06 outside the Greater China region (including Chinese Mainland, Hong Kong, Macao and Taiwan), and Amway Bio will reserve the right of EMB-06 in the Greater China region. Anmai Biotechnology will receive a total down payment of $60 million in cash and Vignette equity, and will have the right to receive up to $575 million in milestone payments for development, listing, and commercialization, as well as revenue sharing based on net sales. EMB-06 is the first TCE molecule developed under the T cell conjugation platform of Anmai Biotechnology, which combines Anmai Biotechnology’s self-developed FIT Ig bispecific antibody platform and CD3 binding domain library, as well as Anmai Biotechnology’s internal new drug ...
- Source: drugdu
- 77
- September 11, 2024
The first domestic new drug for alopecia areata is about to be launched

Recently, Hengrui Medicine announced that its application for marketing authorization of emasitinib sulfate tablets (SHR0302 tablets) was accepted by the National Medical Products Administration for the treatment of severe alopecia areata in adults. It is the first domestic JAK inhibitor to be accepted for marketing approval for alopecia areata indications in China. This also means that after Eli Lilly and Pfizer products have been approved in China, Hengrui is likely to become the first domestic company to enter the domestic alopecia areata market. Severe alopecia areata in adults is the fourth indication reported by emasitinib. Last year, it also reported moderate to severe atopic dermatitis, ankylosing spondylitis, and moderate to severe active rheumatoid arthritis in adults and adolescents aged 12 and above. Referring to the progress of Pfizer’s application for listing of Litixitinib Capsules accepted by the National Medical Products Administration in September 2022, included in the ...
- Source: https://mp.weixin.qq.com/
- 92
- September 11, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.